DETECT— Navigating a New Era in Alzheimer’s Disease: Integrating Disease-Modifying Therapies into Clinical Practice
TeleECHO Series
Pre-Test

Questions marked with a * are required
100%
Contact Information
Which of the following is true regarding the continuum of cognitive impairment when diagnosing and staging Alzheimer’s disease. 
Which of the following are considered disease-modifying therapies for Alzheimer’s disease?
A 66-year-old woman started an anti-amyloid monoclonal antibody 1 month ago for mild dementia associated with Alzheimer’s disease. She reports with her son today with severe headache, confusion, and dizziness. MRI confirms symptomatic amyloid-related imaging abnormalities (ARIA). What should you do for this patient?
Which of the following is true regarding access/costs associated with anti-amyloid therapies?
A 67-year-old man is diagnosed with mild dementia likely due to AD. His wife and caregiver are concerned about cognitive decline and ask about anti-amyloid therapy. When discussing these disease modifying therapies with the patient and his wife, which of the following would you say?
Powered by QuestionPro